The Research Progress of Bufalin in the Treatment of Hepatocellular Carcinoma
Sign Up to like & getrecommendations! Published in 2022 at "OncoTargets and therapy"
DOI: 10.2147/ott.s333233
Abstract: Abstract Hepatocellular carcinoma (HCC) is one of the deadliest cancers in the world with a five-year survival rate of less than 20%. Nonetheless, selecting an appropriate therapeutic agent to inhibit the development of hepatoma cells… read more here.
Keywords: hepatocellular carcinoma; bufalin; progress bufalin; research progress ... See more keywords